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Abstract
Background: In September 2004, the International Committee of Medical Journal Editors (ICMJE) issued a Statement
requiring that all clinical trials be registered at inception in a public register in order to be considered for publication. The
World Health Organization (WHO) and ICMJE have identified 20 items that should be provided before a trial is considered
registered, including contact information. Identifying those scientifically responsible for trial conduct increases
accountability. The objective is to examine the proportion of registered clinical trials providing valid scientific leadership
information.
Methodology/Principal Findings: We reviewed clinical trial entries listing Canadian investigators in the two largest
international and public trial registers, the International Standard Randomized Controlled Trial Number (ISRCTN) register,
and ClinicalTrials.gov. The main outcome measures were the proportion of clinical trials reporting valid contact information
for the trials’ Principal Investigator (PI)/Co-ordinating Investigator/Study Chair/Site PI, and trial e-mail contact address,
stratified by funding source, recruiting status, and register. A total of 1388 entries (142 from ISRCTN and 1246 from
ClinicalTrials.gov) comprised our sample. We found non-compliance with mandatory registration requirements regarding
scientific leadership and trial contact information. Non-industry and partial industry funded trials were significantly more
likely to identify the individual responsible for scientific leadership (OR=259, 95% CI: 95–701) and to provide a contact e-
mail address (OR=9.6, 95% CI: 6.6–14) than were solely industry funded trials.
Conclusions/Significance: Despite the requirements set by WHO and ICMJE, data on scientific leadership and contact e-mail
addresses are frequently omitted from clinical trials registered in the two leading public clinical trial registers. To promote
accountability and transparency in clinical trials research, public clinical trials registers should ensure adequate monitoring
of trial registration to ensure completion of mandatory contact information fields identifying scientific leadership
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Introduction
Starting September 2005, the International Committee of
Medical Journal Editors (ICMJE) required that all clinical trials
be registered at inception in a public register in order to be
considered for publication in member journals [1]. The two largest
registers meeting the ICMJE standards are the International
Standard Randomized Controlled Trial Number (ISRCTN)
(http://www.controlled-trials.com/isrctn/) and ClinicalTrials.gov
(www.clinicaltrials.gov). A major goal of trial registration is to
enhance transparency and accountability in the conduct and
reporting of clinical trials, an objective achieved by making details
about the trial, including source of funding, methods, and design,
publicly available [2,3].
An important component of accountability in clinical research
involves assigning responsibility for the conduct of trials to study
‘chairs’ or principal investigators, who assume the scientific
leadership for these studies. Linking a given trial to an individual
as a matter of public record advances scientific integrity by ensuring
such individuals are available to address any questions or concerns
that may arise from patients, their physicians, or other researchers.
Without the ability to link trials to an individual, accountability
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compared to the investigators listed as authors, thereby providing
a mechanism for ensuring that those responsible for the trial’s
conduct also assume public responsibility for the trial’s outcome.
We reviewed a sample of clinical trial register entries in the
ISRCTN and ClinicalTrials.gov to evaluate the completeness of
data provided on scientific leadership and trial contact information.
Materials and Methods
We used the metaRegister of Clinical Trials (mRCT) to
simultaneously search entries in ISRCTN [5] and ClinicalTrials.
gov [4], the two largest public international clinical trial registers.
The ISRCTN register is owned by ISRCTN, a not-for-profit
organization, and administered by Current Controlled Trials Ltd.
[5]. It was formally launched in May 2003. ClinicalTrials.gov is an
Internet-based register administered by the National Library of
Medicine [4]. The site became active in February 2000. We used
the metaRegister of Clinical Trials (mRCT) to simultaneously
search entries in both registers [6].
As shown in Table 1, ClinicalTrials.gov requires that a central
contact and overall study official be listed in the register entry for
all trials. For the ISRCTN, the ‘priniple investigator’ must be
identified. Providing his/her contact information, including name,
address, and e-mail is compulsory for all trials [7]. Providing a
telephone number is not compulsory. ClinicalTrials.gov mandates
that the name, degree, role, and affiliation of the ‘person(s)
responsible for the overall scientific leadership of the protocol,
including study principal investigator’ be specified for non-IND/
IDE studies [trials that are not associated with United States FDA
Investigational New Drug (IND) or Investigational Device
Exemption (IDE) applications] [8]. ClinicalTrials.gov also requires
that the name, degree, phone number, and e-mail of a central
contact be provided for the overall project.
The WHO Trial Registration Data Set provides a minimum set
of requirements it considers should be included in a trial register
[9]. The Data Set was developed by WHO in an effort to promote
global standardization in trial registration and has been endorsed
by ICMJE [10]. The WHO Registration Data Set mandates the
listing of a ‘Research contact person’, described as the ‘person to
contact for scientific inquiries about the trial.’ [9] See Table 1 for a
summary of the requirements of the WHO and the compliance
with these requirements by ISRCTN, and ClinicalTrials.gov as
stated on their respective websites.
Sampling strategy
As we were interested in the sub-set of trials involving Canadian
investigators, we searched mRCT using the term ‘Canada’ for all
entries up to November 25, 2005. From the generated list of all
trials identifying Canadian study sites or investigators (as either the
study chair, co-ordinating investigator, principal investigator or
site investigator), one of us (JG) manually extracted demographic
information. For each trial identifying at least one Canadian
investigator, data were collected on the following: trial title
(public), funding source(s), recruiting status, study chair/co-
ordinating investigator/principal investigator/site principal inves-
tigator names, and any contact e-mail specific to the trial. As the
information was extracted from publicly available sources, no
ethical approval was necessary.
Funding Source. We classified entries as having non-industry
funding, industry funding, or partial-industry funding. Non-
industry funded trials were defined as those entries listing a
government agency, hospital, university, or other non-profit
source as the sole funder(s). Industry funded trials were defined
as those entries listing a private for-profit corporation, such as a
pharmaceutical or medical devices company, as the sole funder.
Partial-industry funded trials were defined as those entries listing
both an industry funding source and a non-industry source.
Recruitment Status. Entries were classified as either ‘in
progress’ (encompassing ‘ongoing’ ISRCTN entries and ‘not yet
recruiting’and ‘recruiting’ entries inClinicalTrials.gov)or‘no longer
recruiting’ (encompassing entries listed as ‘completed’ or ‘stopped’ in
ISRCTN entries and entries in ClinicalTrials.gov listed as ‘no longer
recruiting’, ‘completed’, ‘suspended’, or ‘terminated’).
Outcomes and Analyses
Our main study outcomes were the proportion of entries
providing the names of those responsible for the scientific
leadership of the trial (PI or Study Chair or Site PI) and the
proportion of entries providing contact e-mail addresses. Among
our primary outcome measures was trial e-mail contact informa-
tion, a variable included among the required registration
parameters for both ISRCTN and Clinicaltrials.gov, as mandated
by the WHO (Table 1). While telephone contact information was
initially considered as an additional measure, it is not a required
Table 1. International Standard Randomized Controlled Trial
Number (ISRCTN) Register and ClinicalTrials.gov adherence to
World Health Organization (WHO) Minimum Registration Data
Set criteria
WHO Item ISRCTN ClinicalTrials.gov
Unique trial number Generated by register Compulsory
Trial registration date Generated by register Compulsory
Secondary IDs Compulsory Optional
Funding source(s) Compulsory Compulsory
Primary sponsor(s) Compulsory; includes
sponsor e-mail
Compulsory
Secondary sponsors(s) Compulsory; includes
sponsor e-mail
Compulsory
Responsible contact person
(Public contact person for the
trial)
Compulsory; includes
contact e-mail
Compulsory; includes
contact e-mail
Research contact person
(Person to contact for
scientific inquiries about
the trial)
Compulsory (field
is ‘Contact Name’)
Compulsory (field is
‘Study Chairs or
Principal
Investigators’)
Title of the study Compulsory Compulsory
Official scientific title of the
study
Compulsory Optional
Countries of Recruitment* Compulsory Compulsory
Condition Compulsory Compulsory
Intervention(s) Compulsory Compulsory
Key inclusion and exclusion
criteria
Compulsory Compulsory
Study type Compulsory Compulsory
Anticipated start date Compulsory Optional
Target sample size Compulsory Optional
Recruitment status Compulsory Compulsory
Primary outcome Compulsory Optional
Key secondary outcomes Compulsory Optional
*Changed in the latest Trial Registration Data Set from ‘research ethics review’
[9]. This change has not yet been reflected in either register.
doi:10.1371/journal.pone.0001610.t001
Accountability in Registration
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reliable variable across the meta-register. Also, the meta-register is
an electronic medium for trial registration, necessitating on-line e-
mail access for successful registration. E-mail is a widely-accepted
means of communication allowing for a traceable and transferable
electronic record of correspondence. Taken together, these factors
support the reliability of e-mail contact information as a primary
outcome measure for our analyses.
To determine whether availability of information varied accord-
ing to recruitment status (in progress versus no longer recruiting),
funding source (non-and partial-industry versus industry-funded),
and trial register (ClinicalTrials.gov versus ISRCTN), we ran two
logistic regression models with presence of scientific leadership
information and presence of e-mail contact information as response
variables. As we wished to examine whether trials initiated and
controlled solely by industry were different from those that were not,
for the logistic regression model, we grouped partial-industry and
non-industry funded trials together: none of these would be as
susceptible to full industry control as trials funded solely by industry.
The six entries failing to list a funding sourcewere excluded from the
logistic regression model. We also used a chi-square test statistic to
assess for an association between the trial register and recruitment
status. Statistical analyses were performed with Stata 8 (Stata Corp,
College Station, Texas) and SAS 9.1 (2002–2003, SAS Institute Inc.,
Cary, North Carolina).
Results
General
Our search yielded 1484 entries in mRCT that included the search
term ‘Canada’. Of these, 163 were from ISRCTN and 1321 from
ClinicalTrials.gov. Entries mentioning Canada in the abstract or in
another context, but without Canadian investigators, were excluded
(n=96). Resultantly, a total of 1388 entries (142 from ISRCTN and
1246 from ClinicalTrials.gov) comprised our sample (Figure 1).
All 1388 entries provided the public study title. A total of 1382
(99.6%) listed the funding source: 686 (50%) were non-industry
funded; 595 (43%) were industry funded; and 101 (7%) were
partial-industry funded. Six and 36 entries respectively did not
provide information about funding source or recruitment status.
Listing of Investigator Names
Overall, 1033/1388 (74%) of trial entries listed the name of the
study chair, PI, co-I, or site PI. For entries reporting recruiting
status, both non- and partial-industry funded trials were
significantly more likely than industry funded trials to list the
name of the study chair, PI, co-I, or site PI. Of 663 non-industry
funded trial entries, 659 (99%) provided this information
compared to only 239 (41%) industry funded trials (Table 2). All
95 partial-industry funded trials reporting recruiting status
provided information on scientific leadership. The adjusted odds
ratio (OR) for non- or partial-industry funded trials providing
names compared to industry trials was 259 (95% CI: 95–701).
Recruitment status was also associated with the provision of
scientific leadership information (Table 2). Studies classified as ‘in
progress’ were significantly more likely to list this information than
studies that were classified as ‘no longer recruiting’ (83% vs. 65%,
OR=1.9, 95% CI: 1.3–2.6). In examining the relationship between
register and provision of scientific leadership information, since 100%
of partial-industry funded studies provided names, the maximum
likelihood estimate is not possible for partial-industry vs. industry. If
we removed partial industry from funding source, applying a logistic
regression model to compare non-industry and industry, the odds
ratio was 242 (95% CI: 89–655). Non-industry funded trials were still
more likely to provide names compared to industry trials.
Listing of E-mail Contact Information
Over one third (n=533; 38%) of trial entries provided
mandatory e-mail contact information. Funding source was
associated with availability of contact e-mail information for those
entries reporting their recruiting status. Of 663 non-industry
funded trials reporting recruiting status, 340 (51%) provided e-
mail contact information compared to 88 of 590 (15%) industry
funded trials (Table 3). Of 95 partial-industry funded trials
reporting recruiting status, 69 (73%) provided e-mail contact
information. The adjusted odds ratio for non-or partial-industry
funded trials providing e-mail addresses compared to industry
trials was 9.6 (95% CI: 6.6–14). When we divided funding source
into three groups (non-industry, partial industry, and industry) and
applied logistic regression models, the odds ratio for non-industry
vs. industry was 6.0 (95% CI: 4.6–7.9), and the odds ratio for
partial-industry vs. industry was 15.1 (95% CI: 9.1–25.1).
We also found an association between recruitment status and
availability of contact e-mail information (Table 3). Studies classified
as ‘in progress’ were significantly more likely to list e-mail contact
information than studies that were classified as ‘no longer recruiting’
(70% vs. 4%, OR=260, 95% CI:118–570) (Table 3). Furthermore,
wefound anassociationbetweentrialregisterandprovisionofe-mail
addresses, with ISRCTN registered trials being more likely to
provide this information (OR=0.01, 95% CI: 0.004–0.03).
Variation by Trial Register: Recruitment Status
We examined whether information on recruitment status was
provided in each register. We determined that recruitment status
was reported significantly more often by entries in ClinicalTrials.
gov than in ISRCTN (99% versus 75%, x
2=305, p,0.0001).
Discussion
Our results reveal that a substantial proportion of registered
clinical trial entries are non-compliant with providing critical study
e-mail contact information that is mandated by the registry.
Industry funded trials were significantly less likely to both identify
individuals primarily responsible for scientific leadership and to
provide trial e-mail contact addresses. Studies that were no longer
in the recruitment phase were also less likely to provide this
information. Significant variation in compliance was found
between entries listed in the two trial registers. Similar data has
recently been reported elsewhere [11].
Clinical trial registration is still in its infancy. Thus, it is not
surprising that in the months following the ICMJE’s September
2005 deadline for mandatory registration, quality issues have
become apparent. Our work demonstrates the discrepancies
between non-industry and industry funded trials with respect to
data entry. Our results also indicate that the data currently being
entered into clinical trial registers, regardless of funding source, are
often not in compliance with either the standards set forth by the
registers themselves or the WHO Registration Data Set, specifically
for the WHO criteria for both ‘responsible contact person’,
including e-mail, and ‘research contact person’, representing
scientific leadership (Table 1).
Around the time that we undertook our study, clinical trial
registries were inundated with newly registered trials as a result of
the introduction of mandatory registration. Instituting methods of
quality assurance, such as verification of registered e-mail
addresses using a unique registration number would be a valuable
means of ensuring information initially entered into the trial’s
registration profile is valid. It is possible that similar means of
quality control have been initiated since we undertook our study.
This is an important issue, which should be addressed in the
Accountability in Registration
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provision of this mandatory information on deficient software, or
electronic limitations. However, one should not overlook that
investigators or sponsors conducting clinical research are fre-
quently using these limitations as loopholes for omitting valuable
information that should allow a given study to be traced back to a
responsible individual.
Our results are of importance to several stakeholder groups,
including patients, health care professionals, and systematic
reviewers with a vested interest in the successful development of
clinical trial registers. Although considerable effort has been made
to improve the quality of reporting in primary studies such as
randomized controlled trials, many of these reports are published
with incomplete information [12,13]. Systematic reviewers require
Table 2. Principal investigator/study chair availability in ISRCTN and ClinicalTrials.gov by funding source and recruitment status
Recruitment status Non-industry funded n=663 Partial-industry funded n=95 Industry funded n=590 Overall n=1348
In progress n=666 372/372 (100%) 68/68 (100%) 111/226 (49%) 554/666 (83%)
No longer recruiting n=682 287/291 (99%) 27/27 (100%) 128/364 (35%) 442/682 (65%)
Total n=1348 659/663 (99%) 95/95 (100%) 239/590 (41%) 993/1348 (74%)
doi:10.1371/journal.pone.0001610.t002
Figure 1.
doi:10.1371/journal.pone.0001610.g001
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clarifications and/or additional data, making the need to contact
investigators even more critical for unpublished studies.
Mechanisms for improving compliance are necessary to ensure
that trial registration continues in a manner that is consistent with
the goals of WHO and ICMJE. Unless all mandatory fields are
completed, the ICMJE currently does not consider a trial
registered [10]. Registers could consider withholding assignment
of a registration identification number for trials with incomplete
data fields, or those trials listing contact information that has not
been confirmed to be both valid and current. Additional
adherence measures should be developed at a policy level among
governments, ethics committees, and funding agencies.
Our work has one limitation. The present study is a part of a
large-scale study evaluating Canadian Academic Health Sciences
Centres, and thus we limited our cohort to trial entries listing at
least one Canadian researcher among the contributing study
investigators. As studies conducted at Canadian sites, and those
involving Canadian investigators, have been demonstrated to
conform to higher research standards with respect to reporting
clinical data [14], and to have stricter privacy rules regulating the
dissemination of personal information, our data sample may not
be entirely representative of an international cohort of registered
clinical trials. There are data to suggest that clinical trials
conducted in other countries might have systematically different
(biased) results. Randomized clinical trials (RCTs) conducted at
Canadian sites are significantly less likely to report uniformly
positive results than are RCTs conducted in east Asia and eastern
Europe [14]. Accordingly, studies conducted at Canadian sites
and/or those involving Canadian researchers may positively
impact the conduct and integrity of a clinical trial. That our
sample, which was limited to this very population, observed major
deficiencies in proper trial registration and accountability in the
clinical research indicates a significant problem even amongst
clinical research supposedly conducted with a higher set of
standards. Resultantly, it is likely that our sample may have under-
represented the problem and provided a conservative estimate of
the prevalence of non-compliance in trial registration. Addition-
ally, identification of a responsible study contact person is amongst
the WHO’s minimum data set for all registered clinical trials. This
is a mandatory piece of contact information for all trials conducted
at any international study site, and in this respect, trials involving
Canadian investigators are not systematically different than any
others.
Our work is consistent with previous studies revealing problems
with data quality in clinical trial registration [11,15]. Zarin et al
[15] demonstrated that in 2670 studies registered in Clinical-
Trials.gov, 24% failed to enter any information in the WHO
criterion ‘Primary Outcome Measure’ field. For the remaining
76%, the level of detail entered was highly variable. Another study
comparing 21 different trial registers demonstrated that only 54%
of entries in various registers provided adequate contact
information, and less than 30% contained information on essential
components of a study, such as outcome measures and
intervention details [11].
Conclusions
We found deficiencies in the availability of information related
to scientific leadership and contact information in two major trial
registers, with trials funded by industry and trials no longer
recruiting being the least compliant. Trial registration may be a
valuable mechanism for promoting transparency in clinical trials,
but methods for improving compliance with the provision of
registration data should be established. A failure to link trials to
study chairs or principal investigators undermines the account-
ability and transparency that trial registration is intended to
promote. Involvement in a clinical trial should be a matter of
permanent public record. Transparency must not be selective in
nature.
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